Loading clinical trials...
Loading clinical trials...
Blood Amyloid-Beta Relationship With Amyloid Plaques and CSF Amyloid-Beta
The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease. Participants will be asked to complete an initial blood collection and cognitive testing, and a subset of participants will be asked to complete a larger blood collection, amyloid PET imaging, and an MRI.
Alzheimer's disease is the most common cause of dementia and currently has no disease-modifying treatments or simple, accurate diagnostic tests. Amyloid beta builds up in the brain and forms plaques in people with Alzheimer's disease, and the buildup of this protein is found decades before symptoms of dementia begin. A blood test may be able to quickly and inexpensively screen people for Alzheimer's disease clinical trials and eventually diagnose Alzheimer's disease in the clinic.
Age
60 - No limit years
Sex
ALL
Healthy Volunteers
No
Washington University School of Medicine
St Louis, Missouri, United States
Start Date
April 9, 2019
Primary Completion Date
January 29, 2024
Completion Date
January 31, 2024
Last Updated
February 13, 2024
1,122
ACTUAL participants
Blood collection, PiB PET/MRI, and cognitive testing
OTHER
Lead Sponsor
Washington University School of Medicine
NCT04123314
NCT07178210
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions